Amisulpride
This antipsychotic works by selectively blocking dopamine receptors in the brain to reduce symptoms such as hallucinations and disorganized thinking. It is used in conditions including schizophrenia, and at low doses may help with depressive symptoms associated with bipolar disorder.
आणविक भार
369.5000 g/mol
LogP
1.50
TPSA
110.00 Ų
लिपिंस्की RO5
उत्तीर्ण
चिकित्सीय क्षेत्र
क्रिया का तंत्र
Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …
2D संरचना
Cite this structure
Embed this structure
SMILES
CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)c(N)cc1OC
InChI
InChI=1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21)
Molecular Formula
C17H27N3O4S
HBD / HBA
2 / 6
घूर्णनीय बंधन
7
भारी परमाणु
25
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
अक्सर पूछे जाने वाले प्रश्न
This antipsychotic works by selectively blocking dopamine receptors in the brain to reduce symptoms such as hallucinations and disorganized thinking. It is used in conditions including schizophrenia, and at low doses may help with depressive symptoms associated with bipolar disorder.
Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.
Yes, Amisulpride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL243712. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 2159. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="amisulpride"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/amisulpride/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/amisulpride/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/amisulpride/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="amisulpride"></drugfyi-drug>